Bafilomycin C1

CHF 180.00
In stock
BVT-0068-M0011 mgCHF 180.00
More Information
Product Details
Synonyms L-681,110A1; 2-Demethyl-2-methoxy-24-methyl-hygrolidin
Product Type Chemical


MW 720.9
CAS 88979-61-7
Source/Host Chemicals Isolated from Streptomyces sp. Gö 14F.
Purity Chemicals ≥98% (HPLC)
Appearance Yellow powder.
Solubility Soluble in 100% ethanol, methanol, DMSO or dimethyl formamide.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Other Product Data

May undergo transformation to methyl ketal on long term storage in methanol. We recommend the use of fresh solutions.

Smiles [H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C/[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](OC(=O)\C=C\C(O)=O)[C@H](C)[C@H](O1)C(C)C
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antibiotic.
  • Specific vacuolar-type H+-ATPase inhibitor.
  • Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases.
  • Antibacterial, insecticidal and anthelmintic.
  • Antifungal activity, especially against C. albicans.
  • Potential anti-osteoporotic agent in treating bone lytic diseases.
  • Neuroprotection inducer.
  • Cytotoxic activity against SMMC7721 HCC cells.
  • Potential candidate for hepatic carcinoma chemotherapy.
Product References
  1. Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity: G. Werner, et al.; J. Antibiot. (Tokyo) 37, 110 (1984)
  2. Purification of vacuolar ATPase with bafilomycin C1 affinity chromatography: T.J. Rautiala, et al.; BBRC 194, 50 (1993)
  3. Bafilolides, potent inhibitors of the motility and development of the free-living stages of parasitic nematodes: E. Lacey, et al.; Int. J. Parasitol. 25, 349 (1995)
  4. Autophagy, bafilomycin and cell death: the "a-B-cs" of plecomacrolide-induced neuroprotection: J.J. Shacka, et al.; Autophagy 2, 228 (2006) (Review)
  5. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis: J. Xu, et al.; Histol. Histopathol. 222, 443 (2007)
  6. Low-dose Bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction: V. Pivtoraiko, et. al.; J. Neurochem. 114, 1193 (2010)
  7. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption-implications for osteoclast quality: A. Neutzsky-Wulff, et. al.; BMC Musculoskel. Disord. 11, 1471 (2010)
  8. Bafilomycins and Odoriferous Sesquiterpenoids from Streptomyces albolongus Isolated from Elephas maximus Feces: N. Ding, et al.; J. Nat. Prod., 79, 799 (2016)
  9. Bafilomycin C1 exert antifungal effect through disturbing sterol biosynthesis in Candida albicans: H. Su, et al.; J. Antibiot. 71, 467 (2018)
  10. Bafilomycin C1 induces G0/G1 cell-cycle arrest and mitochondrial-mediated apoptosis in human hepatocellular cancer SMMC7721 cells: X. Gao, et al.; J. Antibiot. 71, 808 (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.